A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs 852A (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Oct 2009 Planned end date changed from 1 Jun 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 04 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 04 Feb 2009 Additional location identified as reported by ClinicalTrials.gov, last updated 4 Feb 2009.